|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,336.95 INR | +2.62% |
|
+3.38% | +5.18% |
| 16/05 | Dr. Reddy?S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada | CI |
| 15/05 | Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading | MT |
Company Valuation: Dr. Reddy's Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,49,317 | 7,14,500 | 7,67,655 | 10,24,969 | 9,53,168 | 11,13,139 | - | - |
| Change | - | -4.65% | 7.44% | 33.52% | -7.01% | 16.78% | - | - |
| Enterprise Value (EV) 1 | 7,45,052 | 7,03,980 | 7,19,330 | 9,60,383 | 9,28,633 | 10,84,358 | 10,75,153 | 10,52,619 |
| Change | - | -5.51% | 2.18% | 33.51% | -3.31% | 16.77% | -0.85% | -2.1% |
| P/E ratio | 39.2x | 30.4x | 17.1x | 18.4x | 16.9x | 24.4x | 25.3x | 20.7x |
| PBR | 4.29x | 3.76x | 3.33x | 3.63x | 2.86x | 2.96x | 2.68x | 2.42x |
| PEG | - | 1.3x | 0.2x | 0.8x | 13.12x | -1x | -1.9x | 0.9x |
| Capitalization / Revenue | 3.95x | 3.33x | 3.11x | 3.67x | 2.93x | 3.11x | 3.12x | 2.83x |
| EV / Revenue | 3.93x | 3.28x | 2.92x | 3.44x | 2.85x | 3.16x | 3.01x | 2.67x |
| EV / EBITDA | 15.7x | 13.7x | 11.1x | 12.1x | 10.8x | 13.8x | 14.7x | 12.2x |
| EV / EBIT | 23.3x | 20.5x | 13.8x | 14.8x | 13.4x | 18.2x | 21x | 16.3x |
| EV / FCF | 28.7x | 52.3x | 15.1x | 33.1x | 49.1x | 25.9x | 25.2x | 26.8x |
| FCF Yield | 3.48% | 1.91% | 6.61% | 3.02% | 2.04% | 3.85% | 3.96% | 3.73% |
| Dividend per Share 2 | 5 | 6 | 8 | 8 | 8 | 8.08 | 7.486 | 8.229 |
| Rate of return | 0.55% | 0.7% | 0.87% | 0.65% | 0.7% | 0.6% | 0.56% | 0.62% |
| EPS 2 | 23.03 | 28.34 | 54.18 | 66.92 | 67.78 | 51.42 | 52.83 | 64.58 |
| Distribution rate | 21.7% | 21.2% | 14.8% | 12% | 11.8% | 13.2% | 14.2% | 12.7% |
| Net sales 1 | 1,89,722 | 2,14,391 | 2,46,697 | 2,79,164 | 3,25,535 | 3,35,933 | 3,57,047 | 3,93,689 |
| EBITDA 1 | 47,480 | 51,400 | 64,559 | 79,481 | 86,236 | 67,048 | 73,052 | 86,274 |
| EBIT 1 | 31,977 | 34,277 | 52,057 | 64,781 | 69,178 | 46,443 | 51,169 | 64,537 |
| Net income 1 | 19,149 | 23,568 | 45,073 | 55,779 | 56,544 | 42,850 | 44,349 | 54,460 |
| Net Debt 1 | -4,265 | -10,520 | -48,325 | -64,586 | -24,535 | -28,781 | -37,986 | -60,520 |
| Reference price 2 | 903.12 | 861.08 | 924.30 | 1,231.03 | 1,144.05 | 1,336.95 | 1,336.95 | 1,336.95 |
| Nbr of stocks (in thousands) | 8,29,699 | 8,29,771 | 8,30,526 | 8,32,611 | 8,33,152 | 8,32,596 | - | - |
| Announcement Date | 14/05/21 | 19/05/22 | 10/05/23 | 07/05/24 | 09/05/25 | 12/05/26 | - | - |
1INR in Million2INR
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 21.85x | 3.16x | 13.83x | 0.6% | 1.16TCr | ||
| 29.49x | 10.7x | 22.09x | 0.68% | 90TCr | ||
| 24.23x | 5.59x | 15.19x | 2.35% | 55TCr | ||
| 25.6x | 6.33x | 12.92x | 3.26% | 37TCr | ||
| 17.06x | 4.28x | 10.53x | 3.11% | 33TCr | ||
| 20.47x | 5.52x | 13.41x | 3.03% | 28TCr | ||
| 22.87x | 4.75x | 13.5x | 1.84% | 28TCr | ||
| 49.69x | 4.66x | 18.94x | 2.99% | 28TCr | ||
| 13.55x | 4.96x | 10.13x | 3.73% | 21TCr | ||
| 21.22x | 5.75x | 10.04x | 3.09% | 18TCr | ||
| Average | 24.60x | 5.57x | 14.06x | 2.47% | 33.75TCr | |
| Weighted average by Cap. | 25.91x | 6.71x | 15.75x | 2.26% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 500124 Stock
- Valuation Dr. Reddy's Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















